免费获得国外相关药品，最快 1 个工作日回馈药物信息
High Dose Omega 3 in People at Risk for Dementia
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Dementia Inflammation Mild Cognitive Impairment Cognitive Decline SCD Cognitive Dysfunction Pathologic Processes Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurocognitive Disorders Mental Disorder Cognition Disorders | Dietary Supplement: Omega-3 capsules Dietary Supplement: Olive oil | Phase 2 |
Earlier trials with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been moderately promising, but these interventions often suffered from relatively low DHA concentrations. In this trial, the investigators will use a DHA-rich dietary supplement formulated using a self-microemulsifying delivery system to accelerate absorption.
Modification of innate immune activity has already been seen using DHA-rich supplements, and this type of intervention has been shown to ameliorate AD-associated PBMC profiles, and to be associated with improvements in cognition. DHA can cross the BBB, and the resulting CSF concentrations are associated with reduced CSF total tau levels indicating that DHA reduce neurodegeneration, ameliorate Abeta42 induced neuronal damage, and increase microglia Abeta phagocytosis. However, pre-clinical and pre-dementia intervention trials linked to biomarkers for the AD disease process is lacking, and therefore, stratification with respect to stage of disease process has not been performed.
Study cohort: subjects in this pilot study will be recruited from the Norwegian Dementia Disease Initiative (DDI) cohort. The DDI cohort consists of 600 participants with Subjective Cognitive Dedcline (SCD), Mild Cognitive Impairment (MCI) and normal control subjects that have been included at dementia centres across Norway during 2012-2016. Blood samples and cerebrospinal fluid (CSF) have been collected and are stored centrally at Ahus. A comprehensive and highly standarized clinical assessment program has been administered by trained raters (assessors). The investigators are currently performing 2-year follow-up evaluations. Genetic data including APOE-isoforms have been collected as have baseline and follow-up MRIs, PET scans (so far in Oslo and Bergen) and baseline CSF examinations (Ab, total-tau and phosphorus-tau). Cognitive assessments at baseline and follow-up include MMSE and Clinical Dementia Rating (CDR), CERAD 10 word memory test, Clock drawing test, Trail Making Test A and B, Verbal fluency test (FAS), visual recognition test (VOSP silhouettes), Stropp Coloraturas-Word. Data is assembled in a customised database (UiO secure server (TSD)), developed based on XNAT (http://www.xnat.org) and also connected to pipelines for image analysis. A selection from CANTAB MCI test battery including RTI (reaction time), PAL (paired associates learning test), and SWM (spatial working memory).
Study design: All subjects included in the intervention study will have completed 2-year follow-up in the DDI study prior to inclusion and will be on stable medication at least 3 months prior to baseline examinations. Based on the existing electronic CRF for DDI, social e-RCT-CRFs will be developed and programmed into the proprietary XNAT database. Patients fulfilling the inclusion criteria will be identified by a nurse at the memory outpatient clinics and will be given a short information letter regarding the study. Written consent will be asked for. Thereafter, a medical and neurological examination of the patient will be performed, including a medical history and medication use.
This initial pilot study is a minor feasibility study with 40 subjects randomised equally to either of 2 treatment groups for 24 weeks,
Omega-3 3 capsules/day Placebo 3 capsules/day
Each study participant will take 3 capsules in the morning for the 24-week study period. The study may be followed by a larger and statistical valid study. Patients will be randomized (by means of a computerized program) to identically appearing set of capsules with Omega-3 or placebo, 1:1 (produced by BASF AS).
Optional extension study: Participants will be offered another 24-week Omega-3 capsule supply after study end, and a follow-up assessment after 1 year will be conducted, comparing those with and without continuous Omega-3 treatment.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 40 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | A randomized, 24-week parallel-group placebo-controlled (Phase 2) pilot-study of high dose Omega 3 (DHA) in people at risk for dementia |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Masking Description: | Double blinded |
| Primary Purpose: | Prevention |
| Official Title: | A Randomized, 24 Week Parallel-group Placebo-controlled (Phase 2) Pilot-study of High Dose Omega 3 (DHA) in People at Risk for Dementia |
| Actual Study Start Date : | October 1, 2018 |
| Estimated Primary Completion Date : | October 2019 |
| Estimated Study Completion Date : | October 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Arm 1a; Placebo
Valid for the first 24 weeks of the study. Arm 1a: placebo, soft gelatine capsule containing 1000 mg olive oil, refined.
|
Dietary Supplement: Olive oil
Soft gelatine capsule containing 1000 mg olive oil, refined.
|
|
Experimental: Arm 2a; Omega-3 capsules
Valid for the first 24 weeks of the study. Arm 2a; Omega-3, (1000 mg fill weight per capsule) containing omega-3 ethyl ester concentrate with a high proportion of DHA.
|
Dietary Supplement: Omega-3 capsules
BASF AS is the developer of the gelatine capsules containing Omega-3 ethyl ester from fish oil concentrate, as the dietary (nutritional) ingredient. The additional capsule fill ingredients are food additives permitted in food supplements according to Regulation (EC) No 1333/2008 on Food additives.
|
- Cognitive function [ Time Frame: Baseline to 24 weeks ]CERAD 10 word memory test relative to placebo
- Cognitive function [ Time Frame: Baseline to 24 weeks ]Cantab RT test relative to placebo
- Cognitive function [ Time Frame: Baseline to 24 weeks ]Cantab PAL test relative to placebo
- Cognitive function [ Time Frame: Baseline to 24 weeks ]Cantab SWT test relative to placebo
- Blood PBMC betaAmyloid mid-domain assay [ Time Frame: Baseline to 24 weeks ]IVD assay
- CSF betaAmyloid 1-42 [ Time Frame: Baseline to 24 weeks ]IVD assay
- CSF TAU [ Time Frame: Baseline to 24 weeks ]IVD assay
- CSF Phospho-TAU [ Time Frame: Baseline to 24 weeks ]IVD assay
- MRI ASL [ Time Frame: Baseline to 24 weeks ]MRI procedure
- MRI WML [ Time Frame: Baseline to 24 weeks ]MRI procedure
- MRI DTI [ Time Frame: Baseline to 24 weeks ]MRI procedure
| Ages Eligible for Study: | 50 Years to 79 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age > 50 years
- SCD or MCI
- No evidence of neurodegeneration (i.e. CSF phospho and total tau-levels below cut-off)
- Scandinavian mother tongue
- Completed 2-year follow-up in the DDI-study
- Stable medication for at least 3 months prior to baseline exam
Exclusion Criteria:
- Dementia (defined as MMSE < 26 and/or CDR >/= 1))
- Other dementia giving disease than AD
- Other brain disease
- Significant depression
- Unstable coronary heart disease or heart failure in need of treatment
- Systemic inflammatory diseases
- Somatic disease that might affect cognitive function adversely
- Usage of anticoagulants
- Prior radiation- or chemo-therapy possibly affecting CNS
- Relevant cancer or other serious disease with expected survival < 5 years
- Fish meal intake more than 2 times a week
- Regularly intake of Omega-3 supplements over the last 3 months
| Contact: Tormod Fladby, MD PhD | +4792817764 | tormod.fladby@medisin.uio.no | |
| Contact: Erik Christensen, MD PhD | +4795939918 | erik@pre-diagnostics.com |
| Norway | |
| Akershus university hospital, Sykehusveien 25 | Recruiting |
| Lørenskog, Norway, 1478 | |
| Contact: Tormod Fladby +4767960000 tormod.fladby@medisin.uio.no | |
| Principal Investigator: | Tormod Fladby, MD PhD | University Hospital, Akershus |
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Submitted Date ICMJE | March 11, 2019 | ||||
| First Posted Date ICMJE | April 24, 2019 | ||||
| Last Update Posted Date | April 24, 2019 | ||||
| Actual Study Start Date ICMJE | October 1, 2018 | ||||
| Estimated Primary Completion Date | October 2019 (Final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures ICMJE |
Cognitive function [ Time Frame: Baseline to 24 weeks ] CERAD 10 word memory test relative to placebo
|
||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||
| Change History | No Changes Posted | ||||
| Current Secondary Outcome Measures ICMJE |
|
||||
| Original Secondary Outcome Measures ICMJE | Same as current | ||||
| Current Other Pre-specified Outcome Measures | Not Provided | ||||
| Original Other Pre-specified Outcome Measures | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | High Dose Omega 3 in People at Risk for Dementia | ||||
| Official Title ICMJE | A Randomized, 24 Week Parallel-group Placebo-controlled (Phase 2) Pilot-study of High Dose Omega 3 (DHA) in People at Risk for Dementia | ||||
| Brief Summary | The aim of this study is the efficacy of a docosahexaenoic acid (DHA)-rich dietary supplement in improving key dementia-related mechanisms and cognitive function in older people at risk for dementia. This is a randomized placebo-controlled, 24 weeks, phase 2 study of Omega 3 in people with increased risk of dementia. The aim is to explore the effects of DHA on cognitive performance (CERAD 10 word memory tests, TMT A/B, Stroop Color-Word, FAS, VOSP silhouettes, Cantab-test (RT, PAL, SWT)), biological markers (blood: CRP, NLF, TNF-alpha, MCI-1, PBMC Abeta middomain, Omega-3-index, IL, CSF: NLF, sTREM2, Ab 1-42, total and -phospho-tau) and imaging (MRI: standard structural DDI protocol including Freesurfer and WML measurements, DTI and ASL). | ||||
| Detailed Description |
Earlier trials with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been moderately promising, but these interventions often suffered from relatively low DHA concentrations. In this trial, the investigators will use a DHA-rich dietary supplement formulated using a self-microemulsifying delivery system to accelerate absorption. Modification of innate immune activity has already been seen using DHA-rich supplements, and this type of intervention has been shown to ameliorate AD-associated PBMC profiles, and to be associated with improvements in cognition. DHA can cross the BBB, and the resulting CSF concentrations are associated with reduced CSF total tau levels indicating that DHA reduce neurodegeneration, ameliorate Abeta42 induced neuronal damage, and increase microglia Abeta phagocytosis. However, pre-clinical and pre-dementia intervention trials linked to biomarkers for the AD disease process is lacking, and therefore, stratification with respect to stage of disease process has not been performed. Study cohort: subjects in this pilot study will be recruited from the Norwegian Dementia Disease Initiative (DDI) cohort. The DDI cohort consists of 600 participants with Subjective Cognitive Dedcline (SCD), Mild Cognitive Impairment (MCI) and normal control subjects that have been included at dementia centres across Norway during 2012-2016. Blood samples and cerebrospinal fluid (CSF) have been collected and are stored centrally at Ahus. A comprehensive and highly standarized clinical assessment program has been administered by trained raters (assessors). The investigators are currently performing 2-year follow-up evaluations. Genetic data including APOE-isoforms have been collected as have baseline and follow-up MRIs, PET scans (so far in Oslo and Bergen) and baseline CSF examinations (Ab, total-tau and phosphorus-tau). Cognitive assessments at baseline and follow-up include MMSE and Clinical Dementia Rating (CDR), CERAD 10 word memory test, Clock drawing test, Trail Making Test A and B, Verbal fluency test (FAS), visual recognition test (VOSP silhouettes), Stropp Coloraturas-Word. Data is assembled in a customised database (UiO secure server (TSD)), developed based on XNAT (http://www.xnat.org) and also connected to pipelines for image analysis. A selection from CANTAB MCI test battery including RTI (reaction time), PAL (paired associates learning test), and SWM (spatial working memory). Study design: All subjects included in the intervention study will have completed 2-year follow-up in the DDI study prior to inclusion and will be on stable medication at least 3 months prior to baseline examinations. Based on the existing electronic CRF for DDI, social e-RCT-CRFs will be developed and programmed into the proprietary XNAT database. Patients fulfilling the inclusion criteria will be identified by a nurse at the memory outpatient clinics and will be given a short information letter regarding the study. Written consent will be asked for. Thereafter, a medical and neurological examination of the patient will be performed, including a medical history and medication use. This initial pilot study is a minor feasibility study with 40 subjects randomised equally to either of 2 treatment groups for 24 weeks, Omega-3 3 capsules/day Placebo 3 capsules/day Each study participant will take 3 capsules in the morning for the 24-week study period. The study may be followed by a larger and statistical valid study. Patients will be randomized (by means of a computerized program) to identically appearing set of capsules with Omega-3 or placebo, 1:1 (produced by BASF AS). Optional extension study: Participants will be offered another 24-week Omega-3 capsule supply after study end, and a follow-up assessment after 1 year will be conducted, comparing those with and without continuous Omega-3 treatment. |
||||
| Study Type ICMJE | Interventional | ||||
| Study Phase ICMJE | Phase 2 | ||||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: A randomized, 24-week parallel-group placebo-controlled (Phase 2) pilot-study of high dose Omega 3 (DHA) in people at risk for dementia Masking: Triple (Participant, Care Provider, Investigator)Masking Description: Double blinded Primary Purpose: Prevention
|
||||
| Condition ICMJE |
|
||||
| Intervention ICMJE |
|
||||
| Study Arms ICMJE |
|
||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Unknown status | ||||
| Estimated Enrollment ICMJE |
40 | ||||
| Original Estimated Enrollment ICMJE | Same as current | ||||
| Estimated Study Completion Date ICMJE | October 2020 | ||||
| Estimated Primary Completion Date | October 2019 (Final data collection date for primary outcome measure) | ||||
| Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||
| Sex/Gender ICMJE |
|
||||
| Ages ICMJE | 50 Years to 79 Years (Adult, Older Adult) | ||||
| Accepts Healthy Volunteers ICMJE | No | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Listed Location Countries ICMJE | Norway | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT03926351 | ||||
| Other Study ID Numbers ICMJE | REC: 2017/1364 | ||||
| Has Data Monitoring Committee | No | ||||
| U.S. FDA-regulated Product |
|
||||
| IPD Sharing Statement ICMJE | Not Provided | ||||
| Responsible Party | Nora Christine Lund Sørbøe, University Hospital, Akershus | ||||
| Study Sponsor ICMJE | University Hospital, Akershus | ||||
| Collaborators ICMJE |
|
||||
| Investigators ICMJE |
|
||||
| PRS Account | University Hospital, Akershus | ||||
| Verification Date | April 2019 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||
